{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:04Z","timestamp":1740144184152,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019091","name":"Key Research and Development Program of Hunan Province of China","doi-asserted-by":"publisher","award":["2022SK2029"],"award-info":[{"award-number":["2022SK2029"]}],"id":[{"id":"10.13039\/501100019091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800271"],"award-info":[{"award-number":["81800271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Combined antihypertensive therapy has obvious advantages over single drug therapy. Hypertension guidelines fully affirm the efficacy of dual combination in initial antihypertensive therapy. Recent studies have also pointed out that the quadruple combination of very low-dose antihypertensive drugs is superior to single drugs. However, whether low-dose quadruple therapy is better than dual combination is unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>A randomized double-blind crossover clinical trial will be conducted to compare the efficacy and safety of low-dose quadruple antihypertensives (irbesartan 75\u00a0mg\u2009+\u2009metoprolol 23.75\u00a0mg\u2009+\u2009amlodipine 2.5\u00a0mg\u2009+\u2009indapamide 1.25\u00a0mg) with standard-dose dual antihypertensives (irbesartan 150\u00a0mg\u2009+\u2009amlodipine 5\u00a0mg) in the initial treatment of patients with mild to moderate hypertension (140\u2013179\/90\u2013109\u00a0mmHg). Ninety patients are required and will be recruited and randomly assigned in a 1:1 ratio to two crossover groups. Two groups will receive a different combination therapy for 4\u00a0weeks, then switch to the other combination therapy for 4\u00a0weeks, with a 2-week wash-out. Antihypertensive effects and related adverse effects of the two antihypertensive combination treatments will be compared. The primary outcome, i.e., mean 24-h systolic blood pressure in ambulatory blood pressure monitoring, will be assessed via linear mixed-effects model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This statistical analysis plan will be confirmed prior to blind review and data lock before un-blinding and is sought to increase the validity of the QUADUAL trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov, NCT05377203. Registered May 11, 2022, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05377203\">https:\/\/clinicaltrials.gov\/study\/NCT05377203<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07803-1","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T09:02:22Z","timestamp":1705136542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Initial treatment with a single capsule containing half-dose quadruple therapy versus standard-dose dual therapy in hypertensive patients (QUADUAL): statistical analysis plan for a randomized, blinded, crossover trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiexiong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaogang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8369-9694","authenticated-orcid":false,"given":"Weihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"issue":"3","key":"7803_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.11909\/j.issn.1671-5411.2019.03.014","volume":"16","author":"Joint Committee for Guideline R","year":"2019","unstructured":"Joint Committee for Guideline R. 2018 Chinese guidelines for prevention and treatment of hypertension-a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16(3):182\u2013241. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2019.03.014.","journal-title":"J Geriatr Cardiol"},{"issue":"6","key":"7803_CR2","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension (Dallas, Tex: 1979). 2020;75(6):1334\u201357. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15026.","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"issue":"10258","key":"7803_CR3","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"G. B. D. Risk Factors Collaborators","year":"2020","unstructured":"G. B. D. Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England). 2020;396(10258):1223\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(20)30752-2.","journal-title":"Lancet (London, England)"},{"key":"7803_CR4","doi-asserted-by":"publisher","unstructured":"The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases burden in China: an updated summary of 2020. Chinese Circ J. 2021;36(6):521\u201345. https:\/\/doi.org\/10.3969\/j.issn.1000-3614.2021.06.001.","DOI":"10.3969\/j.issn.1000-3614.2021.06.001"},{"issue":"10112","key":"7803_CR5","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/S0140-6736(17)32478-9","volume":"390","author":"J Lu","year":"2017","unstructured":"Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 17 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet (London, England). 2017;390(10112):2549\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(17)32478-9.","journal-title":"Lancet (London, England)"},{"issue":"19","key":"7803_CR6","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.jacc.2017.11.005","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):2199\u2013269. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.005.","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"7803_CR7","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484.","journal-title":"Eur Heart J"},{"issue":"33","key":"7803_CR8","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"issue":"6","key":"7803_CR9","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1097\/HJH.0000000000002072","volume":"37","author":"P Lopez-Jaramillo","year":"2019","unstructured":"Lopez-Jaramillo P, Barbosa E, Molina DI, Sanchez R, Diaz M, Camacho PA, et al. Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. J Hypertens. 2019;37(6):1126\u201347. https:\/\/doi.org\/10.1097\/HJH.0000000000002072.","journal-title":"J Hypertens"},{"issue":"9","key":"7803_CR10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235\u2013481. https:\/\/doi.org\/10.1038\/s41440-019-0284-9.","journal-title":"Hypertens Res"},{"issue":"6","key":"7803_CR11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","volume":"38","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International society of hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982\u20131004. https:\/\/doi.org\/10.1097\/HJH.0000000000002453.","journal-title":"J Hypertens"},{"key":"7803_CR12","volume-title":"Internal medicines","author":"G Junbo","year":"2018","unstructured":"Junbo G, Yongjian X, Chen W. Internal medicines. Beijing: People\u2019s Medical Publishing House; 2018."},{"issue":"4","key":"7803_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2174\/15748847113086660075","volume":"10","author":"P Naik","year":"2015","unstructured":"Naik P, Gandhi H, Pawar V, Giridhar R, Yadav MR. Management of hypertension-journey from single drug therapy to multitargeted ligand therapy: a clinical overview. Curr Clin Pharmacol. 2015;10(4):321\u201346. https:\/\/doi.org\/10.2174\/15748847113086660075.","journal-title":"Curr Clin Pharmacol"},{"issue":"2","key":"7803_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1161\/01.HYP.0000254479.66645.a3","volume":"49","author":"A Mahmud","year":"2007","unstructured":"Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents\u2013a preliminary report. Hypertension (Dallas, Tex: 1979). 2007;49(2):272\u20135. https:\/\/doi.org\/10.1161\/01.HYP.0000254479.66645.a3.","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"issue":"10073","key":"7803_CR15","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/s0140-6736(17)30260-x","volume":"389","author":"CK Chow","year":"2017","unstructured":"Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet (London, England). 2017;389(10073):1035\u201342. https:\/\/doi.org\/10.1016\/s0140-6736(17)30260-x.","journal-title":"Lancet (London, England)"},{"issue":"6","key":"7803_CR16","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2018.10359","volume":"320","author":"R Webster","year":"2018","unstructured":"Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA. 2018;320(6):566\u201379. https:\/\/doi.org\/10.1001\/jama.2018.10359.","journal-title":"JAMA"},{"key":"7803_CR17","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.2147\/DDDT.S286586","volume":"14","author":"SJ Hong","year":"2020","unstructured":"Hong SJ, Sung KC, Lim SW, Kim SY, Kim W, Shin J, et al. Low-dose triple antihypertensive combination therapy in patients with hypertension: a randomized, double-blind, phase II study. Drug Des Dev Ther. 2020;14:5735\u201346. https:\/\/doi.org\/10.2147\/DDDT.S286586.","journal-title":"Drug Des Dev Ther"},{"issue":"10305","key":"7803_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/s0140-6736(21)01922-x","volume":"398","author":"CK Chow","year":"2021","unstructured":"Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet (London, England). 2021;398(10305):1043\u201352. https:\/\/doi.org\/10.1016\/s0140-6736(21)01922-x.","journal-title":"Lancet (London, England)"},{"key":"7803_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ahj.2023.05.019","volume":"264","author":"X Zhao","year":"2023","unstructured":"Zhao X, Chen Y, Yang G, Li X, Tang X, Yang Q, et al. Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): study protocol for a randomized, blinded, crossover trial. Am Heart J. 2023;264:10\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2023.05.019.","journal-title":"Am Heart J"},{"issue":"23","key":"7803_CR20","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/jama.2017.18556","volume":"318","author":"C Gamble","year":"2017","unstructured":"Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dore C, et al. Guidelines for the content of statistical analysis plans in clinical trials. JAMA. 2017;318(23):2337\u201343. https:\/\/doi.org\/10.1001\/jama.2017.18556.","journal-title":"JAMA"},{"key":"7803_CR21","volume-title":"Application of statistical triad theory to experimental design","author":"L Hu","year":"2006","unstructured":"Hu L. Application of statistical triad theory to experimental design. Beijing: People\u2019s Military Medical Press; 2006."},{"key":"7803_CR22","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. https:\/\/doi.org\/10.1136\/bmj.c332.","journal-title":"BMJ"},{"key":"7803_CR23","volume-title":"FDA bioequivalence standards","author":"X Lawrence","year":"2014","unstructured":"Lawrence X, Yu BVL. FDA bioequivalence standards. London: Springer, New York Heidelberg Dordrecht London; 2014."},{"key":"7803_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-81865-4","volume-title":"Analysis of data from randomized controlled trials: a practical guide","author":"JWR Twisk","year":"2021","unstructured":"Twisk JWR. Analysis of data from randomized controlled trials: a practical guide. Switzerland: Springer Nature Switzerland AG; 2021."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07803-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07803-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07803-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T09:04:30Z","timestamp":1705136670000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07803-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7803"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07803-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2024,1,13]]},"assertion":[{"value":"30 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Institutional Review Board of the Third Xiangya Hospital of Central South University (R22023). All patients can voluntarily participate in and withdraw from the study. The purpose and method of the study will be informed in detail and the informed consent will be obtained. All investigators ensure the confidentiality of patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}